Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species?
Mesenchymal stem/stromal cells (MSCs) feature promising potential for cellular therapies, yet significant progress in development of MSC therapeutics and assays is hampered because of remarkable MSC heterogeneity in vivo and in vitro. This heterogeneity poses challenges for standardization of MSC characterization and potency assays as well as for MSC study comparability and manufacturing. This review discusses promising marker combinations for prospective MSC subpopulation enrichment and expansion, and reflects MSC phenotype changes due to environment and age. In order to address animal modelling in MSC biology, comparison of mouse and human MSC markers highlights current common ground of MSCs between species.
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Room 5.24 Clinical Sciences Building, St James's University Hospital, Leeds, LS9 7TF, UK. msjej@leeds.ac.uk.
Elena
E
Jones
Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service, Baden-Württemberg-Hessen gGmbH, Johann-Wolfgang-Goethe University Hospital, Sandhofstrasse 1, D-60528, Frankfurt am Main, Germany. r.schaefer@blutspende.de.
Richard
R
Schäfer
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000378:metabolism; D002478:Cells, Cultured; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000378:metabolism